MeSH term
Frequency | Condition_Probility | Female | 36 | 0.0 |
Humans | 91 | 0.0 |
Pregnancy | 2 | 0.0 |
Adult | 19 | 0.0 |
Aged | 12 | 0.0 |
Immunohistochemistry | 11 | 0.0 |
Male | 19 | 0.0 |
Middle Aged | 16 | 0.0 |
Mutation | 7 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Proto-Oncogene Protein c-met/biosynthesis/*genetics | 2 | 50.0 |
Research Support, Non-U.S. Gov't | 57 | 0.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
*Ubiquitin-Protein Ligases | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
Odds Ratio | 2 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Prognosis | 6 | 0.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
*Receptors, Growth Factor | 2 | 6.0 |
Alleles | 4 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Catechol O-Methyltransferase/*genetics | 3 | 3.0 |
Chi-Square Distribution | 2 | 0.0 |
Comparative Study | 9 | 0.0 |
Gene Frequency/genetics | 2 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Methionine/*genetics | 2 | 13.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Valine/*genetics | 2 | 9.0 |
Disease Progression | 2 | 0.0 |
Gene Expression | 6 | 0.0 |
Neoplasm Metastasis | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Signal Transduction | 13 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Blotting, Northern | 4 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Proto-Oncogene Protein c-met/*metabolism | 16 | 26.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Survival Analysis | 2 | 0.0 |
Tumor Cells, Cultured | 20 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Animals | 44 | 0.0 |
Cell Division | 2 | 0.0 |
Cell Line | 12 | 0.0 |
Hepatocyte Growth Factor/*pharmacology | 4 | 2.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Transfection | 12 | 0.0 |
Blotting, Western | 9 | 0.0 |
Neoplasm Invasiveness | 7 | 0.0 |
Phenotype | 9 | 0.0 |
Phosphorylation | 16 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 4 | 0.0 |
*Adaptor Proteins, Signal Transducing | 8 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Hepatocyte Growth Factor/*metabolism | 8 | 7.0 |
Mice | 28 | 0.0 |
Mice, Nude | 8 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Phosphotyrosine/metabolism | 4 | 0.0 |
Precipitin Tests | 3 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
*Signal Transduction | 7 | 0.0 |
Autocrine Communication | 3 | 4.0 |
COS Cells | 4 | 0.0 |
Cells, Cultured | 6 | 0.0 |
Dogs | 7 | 0.0 |
Enzyme Activation | 6 | 0.0 |
Models, Biological | 2 | 0.0 |
3T3 Cells | 8 | 0.0 |
Mutagenesis | 3 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
Binding Sites | 7 | 0.0 |
Molecular Sequence Data | 17 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Hepatocyte Growth Factor/pharmacology | 3 | 4.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Mice, Transgenic | 8 | 0.0 |
Models, Molecular | 5 | 0.0 |
Phosphoproteins/metabolism | 3 | 0.0 |
Protein Binding | 5 | 0.0 |
Proteins/*metabolism | 3 | 0.0 |
Proto-Oncogene Protein c-met/genetics/*metabolism | 5 | 29.0 |
Adenoma/metabolism | 2 | 5.0 |
DNA Probes | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Cell Movement | 2 | 0.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
Hepatocyte Growth Factor/*biosynthesis | 2 | 6.0 |
Morphogenesis | 4 | 1.0 |
Proto-Oncogene Protein c-met/*biosynthesis | 3 | 15.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
MAP Kinase Signaling System/*physiology | 2 | 2.0 |
In Vitro | 3 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Tumor Markers, Biological/metabolism | 2 | 0.0 |
Hela Cells | 4 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Proto-Oncogene Protein c-met/*physiology | 3 | 27.0 |
Proto-Oncogene Proteins/*physiology | 4 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 28 | 0.0 |
src Homology Domains | 2 | 0.0 |
DNA/metabolism | 2 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Time Factors | 6 | 0.0 |
Up-Regulation | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Child | 3 | 0.0 |
English Abstract | 3 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Dimerization | 2 | 0.0 |
Cell Division/drug effects | 4 | 0.0 |
*Dietary Supplements | 2 | 3.0 |
Transcription, Genetic | 2 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Hepatocyte Growth Factor/genetics/*metabolism | 2 | 9.0 |
Mice, Inbred C57BL | 3 | 0.0 |
RNA, Messenger/isolation & purification | 2 | 2.0 |
Carcinoma/*genetics/pathology | 2 | 3.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 2 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Breast Neoplasms/*genetics/pathology | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Cell Movement/physiology | 3 | 1.0 |
Tumor Cells, Cultured/drug effects/pathology | 2 | 4.0 |
*Chickens | 2 | 22.0 |
Feces/*chemistry | 2 | 7.0 |
Methionine/*administration & dosage | 2 | 50.0 |
Odors/*analysis | 2 | 40.0 |
Hepatocyte Growth Factor/*physiology | 3 | 5.0 |
Tyrosine/metabolism | 4 | 0.0 |
Base Sequence | 7 | 0.0 |
Pedigree | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
*Neoplasm Metastasis | 2 | 2.0 |
Rats | 2 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
Point Mutation | 4 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Tyrosine/chemistry | 2 | 1.0 |
Proto-Oncogene Protein c-met/metabolism | 3 | 4.0 |
Adenocarcinoma/metabolism/pathology | 2 | 3.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Methionine/*metabolism | 2 | 10.0 |
Oxidation-Reduction | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Linear Models | 2 | 0.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Hepatocyte Growth Factor/metabolism | 3 | 5.0 |
Ligands | 4 | 0.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Proto-Oncogene Protein c-met | 9 | 6.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Ubiquitins/*metabolism | 2 | 1.0 |
Genotype | 2 | 0.0 |
*Neoplasm Invasiveness | 2 | 2.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Peptides/chemistry | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
